应用血清PIVKA-II诊断肝细胞癌研究进展*

doi:10.3969/j.issn.1672-5069.2019.06.040

摘要/Abstract

摘要： 原发性肝癌（PLC）是我国最常见的恶性肿瘤之一,而早期诊断是对肝癌治疗能否获益的关键。维生素K缺乏或拮抗剂II诱导的蛋白（PIVKA-II）是近年来获得研究者广泛关注的一种新型肿瘤标志物,比甲胎蛋白诊断敏感性高。本文介绍了其在肝癌发病机制研究和临床应用方面的价值。

关键词: 原发性肝癌, 肿瘤标志物, 维生素K缺乏或拮抗剂II诱导的蛋白, 诊断

Abstract: Primary liver cancer （PLC） is one of the most common malignant tumors in China. Early diagnosis of liver cancer is crucial for the outcome of patients with PLC. Protein induced by vitamin K absence or antagonist II（PIVKA-II） is a new serum tumor marker documented in recent years. It has a diagnostic value for hepatocellular carcinoma,reportedly better than the widely used serum tumor marker alpha-fetoprotein （AFP）. In this paper,we reviewed the progress of PIVKA-II in the fundamental research and clinical application.

Key words: Hepatocellular carcinoma, Tumor marker, Protein induced by vitamin K absence or antagonist II, Diagnosis

邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.

Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.

参考文献

[1] Chen WQ,Zheng RS,Zhang SW.Liver cancer incidence and mortality in China,2009. Chin J Cancer,2013,32(4):162-169.
[2] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015. CA Cancer J Clin,2016,66(2):115-132.
[3] May M.Statistics:attacking an epidemic. Nature,2014,509(7502):S50-51.
[4] Singal AG,Marrero JA,Yopp A.Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw,2014,12(3):375-382.
[5] Bruix J,Sherman M.Management of hepatocellular carcinoma:an update. Hepatology,2011,53(3):1020-1022.
[6] EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma. J Hepatol,2012,56(4):908-943.
[7] Zhu R,Yang J,Xu L,et al.Diagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma:a Meta-analysis. Gastroenterol Res Pract,2014,2014:529314.
[8] Liebman HA,Furie BC,Tong MJ,et al.Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med,1984,310(22):1427-1431.
[9] Lok AS,Sterling RK,Everhart JE,et al.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology,2010,138(2):493-502.
[10] Inagaki Y,Tang W,Makuuchi M,et al.Clinical and molecular insights into the hepatocellular carcinoma tumor marker des-γ-carboxyprothrombin. Liver Int,2011,31(1):22-35.
[11] Fajardo-Puerta AB,Mato PM,Frampton AE,et al.Gene of the month:HGF. J Clin Pathol,2016,69(7):575-579.
[12] Suzuki M,Shiraha H,Fujikawa T,et al.Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem,2005,280(8):6409-6415.
[13] Ma M,Qu XJ,Mu GY,et al.Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin. Chemotherapy,2009,55(1):28-35.
[14] Fujikawa T,Shiraha H,Ueda N,et al.Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem,2007,282(12):8741-8748.
[15] Wang SB,Cheng YN,Cui SX,et al.Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis,2009,26(5):469-477.
[16] Fujikawa T,Shiraha H,Yamamoto K.Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Acta Med Okayama,2009,63(6):299-304.
[17] Zhang YS,Chu JH,Cui SX,et al.Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. Cell Physiol Biochem,2014,34(3):903-915.
[18] Dhir M,Melin AA,Douaiher J,et al.A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg,2016,263(6):1112-1125.
[19] Bruix J,Reig M,Sherman M.Evidence-based diagnosis,staging,and treatment of patients with hepatocellular carcinoma. Gastroenterology,2016,150(4):835-853.
[20] Toyoda H,Kumada T,Tada T,et al.Tumor markers for hepatocellular carcinoma:simple and significant predictors of outcome in patients with HCC. Liver Cancer,2015,4(2):126-136.
[21] Wang CH,Wey KC,Mo LR,et al.Current trends and recent advances in diagnosis,therapy,and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev,2015,16(9):3595-3604.
[22] Weitz IC,Liebman HA.Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma:a critical review. Hepatology,1993,18(4):990-997.
[23] Nakamura S,Nouso K,Sakaguchi K,et al.Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol,2006,101(9):2038-2043.
[24] Baek YH,Lee JH,Jang JS,et al.Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology,2009,56(91-92):763-767.
[25] Ji J,Wang H,Li Y,et al.Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis b virus-related hepatocellular carcinoma in China:a large-scale,multicentre study. PLoS One,2016,11(4):e0153227.
[26] Yamamoto K,Imamura H,Matsuyama Y,et al.Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol,2009,16(10):2795-2804.
[27] Poté N,Cauchy F,Albuquerque M,et al.Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol,2015,62(4):848-854.
[28] Shirabe K,Itoh S,Yoshizumi T,et al.The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol,2007,95(3):235-240.
[29] Shimada M,Yonemura Y,Ijichi H,et al.Living donor liver transplantation for hepatocellular carcinoma:a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc,2005,37(2):1177-1179.
[30] Kim DY,Choi MS,Lee JH,et al.Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol,2006,12(43):6992-6997.
[31] Kim JM,Hyuck C,Kwon D,et al.Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma. World J Surg,2013,37(6):1371-1378.
[32] Lou J,Zhang L,Lyu S,et al.Biomarkers for hepatocellular carcinoma. Biomark Cancer,2017,9:1-9.
[33] Forner A,Reig M,Bruix J.Hepatocellular carcinoma,Lancet,2018. 391:1301-1314.
[34] Juárez-Hernández E,Motola-Kuba D,Chávez-Tapia NC,et al.Biomarkers in hepatocellular carcinoma:an overview. Expert Rev Gastroenterol Hepatol,2017,11(6):549-558.
[35] Toyoda H,Kumada T,Tada T,et al.Prognostic significance of a combination of pre-and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol,2012,57(6):1251-1257.
[36] Chon YE,Choi GH,Lee MH,et al.Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer,2012,131(10):2332-2341.
[37] Lee MH,Kim SU,Kim dY,et al. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol,2012,27(2):313-322.
[38] Park SJ,Jang JY,Jeong SW,et al.Usefulness of AFP,AFP-L3,and PIVKA-II,and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore),2017,96(11):e5811.

应用血清PIVKA-II诊断肝细胞癌研究进展^*

Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[3]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[4]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[5]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[6]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[7]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[8]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[9]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[10]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[14]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[15]	张骏飞, 许何明, 宋海燕, 董静, 潘劲劲, 陈照林, 徐军, 陈从新, 刘波. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征：巴黎标准诊断中国患者灵敏度低[J]. 实用肝脏病杂志, 2019, 22(4): 537-540.